JGC
NVO

J. Goldman & Co’s Novo Nordisk NVO Stock Holding History

J. Goldman & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-380,000
Closed -$14M – 857
2026
Q1 		$14M Buy
380,000
+139,900
+58% +$6.63M 0.41% 69
2025
Q4 		$12.2M Buy
240,100
+200,100
+500% +$10.2M 0.32% 89
2025
Q3 		$2.22M Sell
40,000
-144,200
-78% -$8.44M 0.06% 271
2025
Q2 		$12.7M Buy
+184,200
New +$12.5M 0.3% 108
2025
Q1 		– Sell
-40,000
Closed -$3.44M – 583
2024
Q4 		$3.44M Sell
40,000
-70,000
-64% -$7.57M 0.09% 225
2024
Q3 		$13.1M Buy
+110,000
New +$14.7M 0.37% 84
2023
Q4 		– Sell
-35,000
Closed -$3.18M – 433
2023
Q3 		$3.18M Buy
+35,000
New +$3.08M 0.11% 162

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

J. Goldman & Co's NVO Position: Q2 2026 in Review

J. Goldman & Co sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 11,335 shares — an estimated $417K sold.

J. Goldman & Co first reported a position in NVO in Q1 2024 and held it in 4 quarters. The position peaked at $2.77M in Q3 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • J. Goldman & Co reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 11,335 Novo Nordisk shares in Q2 2026, an estimated $417K.
  • J. Goldman & Co first reported a position in Novo Nordisk in Q1 2024 and held it in 4 quarters.
  • J. Goldman & Co's Novo Nordisk position peaked at $2.77M in Q3 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.